Skip to main content
OpenTrials

Clinical trial condition

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Explore clinical trials studying Precursor T-Cell Lymphoblastic Leukemia-Lymphoma. Study availability and eligibility vary by location and protocol.

294 public trials 62 recruiting studies
Refine in advanced search Browse all conditions

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma trial results

Completed

Nivolumab in Treating Patients With HTLV-Associated T-Cell Leukemia/Lymphoma

NCT02631746

Conditions
Acute Adult T-Cell Leukemia/Lymphoma, Adult T-Cell Leukemia/Lymphoma, Chronic Adult T-Cell Leukemia/Lymphoma, +23 more
Locations
  • Johns Hopkins University/Sidney Kimmel Cancer Center Baltimore, Maryland, United States
  • National Institutes of Health Clinical Center Bethesda, Maryland, United States
  • NCI - Center for Cancer Research Bethesda, Maryland, United States
  • Montefiore Medical Center-Einstein Campus The Bronx, New York, United States
View Trial Details
Completed

Sapanisertib in Treating Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia

NCT02484430

Conditions
B Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative, +25 more
Locations
  • Mayo Clinic Hospital in Arizona Phoenix, Arizona, United States
  • Mayo Clinic in Arizona Scottsdale, Arizona, United States
  • City of Hope Comprehensive Cancer Center Duarte, California, United States
  • Los Angeles General Medical Center Los Angeles, California, United States
View all 14 locations
View Trial Details
Completed

Valemetostat Tosylate (DS-3201b) Phase 2 Study in Relapsed or Refractory Adult T-cell Leukemia/Lymphoma

NCT04102150

Conditions
Adult T-Cell Leukemia/Lymphoma, Hematologic Diseases, Hemic and Lymphatic Diseases, +10 more
Locations
  • Nagoya City University Hospital Nagoya, Aichi-ken, Japan
  • National Cancer Center Hospital East Kashiwa-shi, Chiba, Japan
  • Ehime University Hospital Tōon-shi, Ehime, Japan
  • Kyushu University Hospital Fukuoka, Japan
View all 24 locations
View Trial Details
Completed

Investigation of Safety, Tolerability and Maximum Tolerated Dose (MTD) of BI 2536 in Patients With Recurrent Advanced Aggressive Non-Hodgkin's Lymphoma (NHL)

NCT00243087

Conditions
Burkitt Lymphoma, DNA Virus Infections, Epstein-Barr Virus Infections, +25 more
Locations
  • Lombardi Comprehensive Cancer Center at Georgetown University Medical Center Washington D.C., District of Columbia, United States
  • UNMC Eppley Cancer Center at the University of Nebraska Medical Center Omaha, Nebraska, United States
  • James P. Wilmot Cancer Center at University of Rochester Medical Center Rochester, New York, United States
  • M. D. Anderson Cancer Center at University of Texas Houston, Texas, United States
View Trial Details
Completed

KW-0761 or Investigator's Choice in Subjects With Previously Treated Adult T-cell Leukemia-Lymphoma (ATL)

NCT01626664

Conditions
Adult T-Cell Leukemia-Lymphoma, Hematologic Diseases, Hemic and Lymphatic Diseases, +12 more
Locations
  • Cedars-Sinai Medical Center Los Angeles, California, United States
  • University of Miami / Sylvester Comprehensive Cancer Center Miami, Florida, United States
  • Northwestern University Chicago, Illinois, United States
  • National Cancer Institute Bethesda, Maryland, United States
View all 20 locations
View Trial Details

Related conditions